CAR T cell therapy for brain metastases
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new kind of cell therapy that uses your own immune cells (modified to attack cancer) to treat brain metastases. It may help people whose cancer has spread to the brain and hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed cancer diagnosis and a brain metastasis that is getting worse or is new.
- Tumor tissue must show a marker called CD70.
- You need to be fairly active and able to care for yourself (Karnofsky score of 70% or higher).
- Your blood counts, liver, and kidney function must be within certain limits.
- You cannot have HIV or other conditions that weaken the immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cells that are designed to target and kill brain tumor cells that have a specific marker called CD70. It is for children and young adults with certain high-grade brain tumors, either newly diagnosed or that have come back.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This Phase 1 study tests a type of immune therapy (CAR T cells) for children with brain tumors that come back or do not respond to standard treatment. The cells are given after chemotherapy that temporarily lowers the body’s immune system, which may help the CAR T cells work better.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.